Is your ketamine therapy quote reasonable for your area?

Costs range from $100 to $1,500+ per session depending on format. IV infusions: $400-$800/session (median $600), 6 sessions typical, total $2,400-$4,800. Intramuscular: $250-$800/session, 6 sessions. Spravato nasal spray: $590-$1,200/session (often insurance-covered). At-home sublingual: $100-$350/month. Ketamine-assisted psychotherapy: $500-$1,200/session. (Source: ASKP3 provider surveys)

Insurance coverage depends on treatment format. Spravato is covered by 65-75% of commercial plans. IV infusions are covered by only 5-15% of plans. At-home sublingual programmes are covered by fewer than 5% of plans. Janssen's copay assistance programme can reduce Spravato out-of-pocket costs to as low as $10 per session for eligible patients. Some clinics accept HSA and FSA payments. (Source: KFF insurance surveys; Janssen CarePath)

Clinical doses (typically 0.5 mg/kg for IV infusions) produce a dissociative state lasting 40-60 minutes, described as a sense of floating, mild visual distortions, and emotional detachment. This is substantially different from anaesthetic or recreational doses. Clinics monitor patients throughout and require a 1-2 hour observation period. The dissociative effects resolve completely within a few hours. Patients are advised not to drive for the remainder of the treatment day. (Source: FDA Spravato prescribing information; JAMA Psychiatry meta-analyses)

Standard infusions use racemic ketamine delivered intravenously over 40 minutes. This is an off-label use, legal when prescribed by a licensed provider. Spravato uses only the S-enantiomer (esketamine) as a nasal spray and received FDA approval for treatment-resistant depression in 2019. Spravato must be administered in a certified healthcare setting under the REMS programme with mandatory 2-hour observation. Per-session costs are comparable before insurance, but Spravato is covered by most commercial plans while infusions typically are not. Both produce similar response rates of approximately 50-70% in treatment-resistant patients. (Source: FDA; JAMA Psychiatry)

A standard initial course involves 6 sessions over 2 to 3 weeks for IV infusions. Spravato's FDA-approved protocol calls for 8 sessions during the induction phase (twice weekly for 4 weeks), followed by once-weekly sessions for 4 weeks, then once weekly or fortnightly for maintenance. Most patients notice improvement within the first 2 to 3 sessions. After the initial course, maintenance sessions are usually needed to sustain benefits, with frequency varying from every 2 weeks to every 2 months depending on individual response. The total first-year cost at a median IV rate of $600 per session might include 6 initial plus 6 to 12 maintenance sessions, totalling $7,200 to $10,800. (Sources: ASKP3; FDA Spravato prescribing information)

Ketamine has been used as an anaesthetic since 1970 and has a well-established safety profile at clinical doses. Common side effects during treatment include dissociation, dizziness, nausea, increased blood pressure, and drowsiness, all of which typically resolve within 2 hours. Serious adverse events are rare when treatment is administered by trained providers with appropriate monitoring. The primary safety concerns are abuse potential (ketamine is a Schedule III controlled substance), bladder toxicity with long-term high-dose use (not typically seen at clinical doses), and cardiovascular stress in patients with uncontrolled hypertension. Patients with a history of psychosis, active substance use disorder, or aneurysmal vascular disease are generally excluded from treatment. (Sources: FDA; JAMA Psychiatry; NIMH)

At-home ketamine therapy has become widely available through telehealth providers and now represents roughly 30% of the market. Companies like Mindbloom, Nue Life, and Better U offer programmes where a psychiatrist evaluates by video call, prescribes sublingual ketamine lozenges, and provides ongoing monitoring. Costs typically range from $150 to $350 per month. Lozenges have lower bioavailability (roughly 25-30%) than IV infusions but produce milder dissociative effects. At-home therapy is not appropriate for patients with severe symptoms, active suicidal ideation, or a history of substance misuse. Most at-home programmes are not covered by insurance. (Sources: ASKP3; FDA guidance)

Generic SSRIs like sertraline cost $4 to $30 per month, making them dramatically cheaper per month. However, patients seeking ketamine therapy have typically failed 3 to 5 prior medications, accumulating years of psychiatrist visits, therapy, and productivity losses. A 2023 health economics analysis estimated that the average treatment-resistant depression patient spends $15,000 to $25,000 annually in direct and indirect costs before finding an effective treatment. A ketamine infusion course that achieves remission can represent a net cost saving within the first year when reduced emergency visits, hospitalisations, and disability days are factored in. Spravato with insurance coverage can cost $10 to $150 per session, making it competitive with ongoing psychiatric care. (Sources: JAMA Psychiatry; ASKP3)